US 10,376,499 B2
Combination therapy for treatment of resistant bacterial infections
Boudewijn Lodewijk Maria DeJonge, Waltham, MA (US); Thomas Francois Durand-Reville, Belmont, MA (US); Jeroen Cunera Verheijen, Westborough, MA (US); Ruben Tommasi, Stow, MA (US); and John Mueller, Waltham, MA (US)
Assigned to Entasis Therapeutics Limited, Altrincham (GB)
Filed by Entasis Therapeutics Limited, Altrincham (GB)
Filed on Apr. 9, 2018, as Appl. No. 15/947,959.
Application 15/947,959 is a division of application No. 15/527,091, granted, now 9,968,593, previously published as PCT/US2015/061076, filed on Nov. 17, 2015.
Claims priority of provisional application 62/080,667, filed on Nov. 17, 2014.
Prior Publication US 2018/0289681 A1, Oct. 11, 2018
Int. Cl. A61K 31/439 (2006.01); C07D 471/08 (2006.01); A61K 31/197 (2006.01); A61K 31/407 (2006.01); A61K 31/43 (2006.01)
CPC A61K 31/439 (2013.01) [A61K 31/197 (2013.01); A61K 31/407 (2013.01); A61K 31/43 (2013.01); C07D 471/08 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A combination consisting essentially of the β-lactamase inhibitor:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, and sulbactam, or a pharmaceutically acceptable salt thereof.